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Cardiac tissue requires a persistent production of energy in order to exert its pumping
function. Therefore, the maintenance of this function relies on mitochondria that
represent the “powerhouse” of all cardiac activities. Mitochondria being one of the key
players for the proper functioning of the mammalian heart suggests continual regulation
and organization. Mitochondria adapt to cellular energy demands via fusion-fission
events and, as a proof-reading ability, undergo mitophagy in cases of abnormalities.
Ca2+ fluxes play a pivotal role in regulating all mitochondrial functions, including
ATP production, metabolism, oxidative stress balance and apoptosis. Communication
between mitochondria and others organelles, especially the sarcoplasmic reticulum is
required for optimal function. Consequently, abnormal mitochondrial activity results in
decreased energy production leading to pathological conditions. In this review, we will
describe how mitochondrial function or dysfunction impacts cardiac activities and the
development of dilated cardiomyopathy.
Keywords: mitochondria, cardiomyocytes, cardiomyopathies, organoids model, sarcoplasmic reticulum, Ca
ATPase (SERCA) 2+, calcium, heart function
INTRODUCTION
Mitochondria are highly dynamic organelles, universally recognized as the “powerhouse” of
eukaryotic cells, especially in those that require high-energy demand such as cardiomyocytes
(Nan et al., 2017). In these cells mitochondria occupy 30% of the total volume of the cell
and supply, through oxidative phosphorylation (OXPHOS), approximately 6 kg of adenosine
triphosphate (ATP) per day that is required to sustain cardiac function (Cao and Zheng, 2019). In
addition to their pivotal role in energy production, mitochondria are the central hub of cellular
metabolism providing metabolites for biosynthesis and also producing reactive oxygen species
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(ROS). Under physiological conditions ROS act as second
messengers that are maintained at low concentrations by the
scavenging system present in the cell. However, ROS are
hyper-produced in many cardiovascular diseases (CVDs), which
impairs heart function (Murphy et al., 2016).
It is well established that mitochondrial calcium (Ca2+) fluxes
are a key regulator of cardiac function, controlling not only ATP
production and mitochondrial metabolism, but also playing a
pivotal role in the modulation of muscle contraction (Walsh
et al., 2009). In cardiomyocytes mitochondria are well organized
and in close proximity to the sarcoplasmatic reticulum (SR),
where most cellular Ca2+ is stored (Frederick and Shaw, 2007).
Therefore, mitochondria are highly sensitive to Ca2+ oscillations.
The release of Ca2+ from SR to mitochondria ensures a balanced
activation of SR ATPase and mitochondrial ATP synthesis;
all of which contribute to controlling the energy metabolism
within a cell (Balaban et al., 2003). Hence, the maintenance of
Ca2+ homeostasis is a fundamental requirement for optimal
mitochondrial function as mitochondria are a key checkpoint
regulating cell survival and cell death.
It is thus not surprising that the maintenance of efficient inter-
organelle-communication as well as a conserved “mitochondrial
quality control” system (MQC), are fundamental for sustaining
mitochondrial bioenergetics demand and metabolic functions
(Campos et al., 2016). The term MQC refers to mitochondrial
fusion and fission machinery (also called mitochondrial
dynamics) and autophagy (called mitophagy when pertaining
to mitochondria) (Fan et al., 2020). As we will explain in detail
in this review, mitochondrial fusion has the ability to respond
to high-energy demand conditions by recovering mitochondria
that have been damaged and creating elongated interconnected
mitochondrial networks. Fission, however, is the process by
which dysfunctional mitochondria are separated and segregated
away from healthy ones. These dysfunctional mitochondria
may be subsequently either recovered or eliminated through
mitophagy (Murphy et al., 2016; Fan et al., 2020; Forte et al.,
2020; Oh et al., 2020). These complex processes provide the
balance for maintaining proper mitochondrial dynamics through
regulation of mitochondrial size, shape and number (Youle and
Karbowski, 2005; Piquereau et al., 2013).
An increasing number of studies on cardiac mitochondria
have determined that dysfunction in their structure and function
contributes to the pathogenesis of CVD including dysrhythmias,
ischemia-reperfusion injury (IRI) and cardiomyopathies (CMPs);
all of which culminate in end-stage heart failure (HF) (Brown and
O’Rourke, 2010; Cadenas et al., 2010; Rosca and Hoppel, 2010;
Verdejo et al., 2012).
In this review, we will provide an overview of the main
functions of mitochondria within cardiac tissue. Furthermore,
we will discuss the involvement of mitochondrial impairment in
CVD, focusing our attention on dilated cardiomyopathy (DCM)
leading to heart failure. Dilated cardiomyopathy is associated
with decreased mitochondrial biogenesis and we will examine
DCM subtypes and how mitochondria are dysregulated in these
conditions. We will highlight the paucity of targeted treatments
for DCM and the necessity for understanding the molecular
mechanisms involved in DCM onset and progression. Finally,
we will the need for new methods to tease out the complexities
of dilated cardiomyopathy, such as the potential use of cardiac
organoids to investigate the underlying molecular mechanisms
of cardiac function and to develop new targeted therapies for
dilated cardiomyopathy.
MITOCHONDRIAL FUNCTIONS IN THE
HEART
Bioenergetics, Ca2+ Homeostasis, Cell
Death
In heart mitochondria, the primary source of carbons for ATP
production relies on fatty acid oxidation (FAO) (Figure 1).
Products of beta-oxidation are directed into the tricarboxylic acid
cycle (TCA): the starting compound acetyl-CoA enters the cycle
and undergoes a series of reactions where electrons are extracted
from TCA intermediates in the form of the reducing equivalents
NADH and FADH2 and in turn fueling the electron transport
chain (ETC) for ATP synthesis (Murphy et al., 2016; Martínez-
Reyes and Chandel, 2020). The ETC creates an electrochemical
gradient (19m is −180 mV) along the intermitochondrial
membrane (IMM) interface which acts as a driving force for
mitochondrial Ca2+ uptake (Giorgi et al., 2012, 2018b; Figure 1).
Mitochondria are calcium-buffering organelles in which under
resting conditions mitochondrial Ca2+ concentrations are kept
low, but after a stimulus Ca2+ is transferred from the SR
into the mitochondria that transiently and rapidly takes up
large quantities of Ca2+ (Giorgi et al., 2018a,b). Lastly, Ca2+
is extruded from mitochondria by the Na+/ Ca2+ antiporter
(NCLX) (Giorgi et al., 2018a; Figure 1).
However, under pathological conditions, a cytosolic Ca2+
overload initiates a large and persistent Ca2+ uptake by
mitochondria, which triggers the opening of the mitochondrial
permeability transition pore (mPTP; a nonspecific pore)
(Figure 1; Giorgi et al., 2012; Morganti et al., 2018). mPTP
allows for free passage of small molecules and ions (<1.5 kDa)
across the IMM, leading to membrane potential dissipation,
and consequent imbalance in ATP production, mitochondrial
swelling and mitochondrial outer membrane (OMM) rupture
all of which cause regulated cell death (RCD) through either
apoptosis or necrosis (Figure 1; Bonora et al., 2015). The
activation of one of these cell death pathways depends upon
the severity of the damage and the kinetics of the pore opening
(Javadov and Karmazyn, 2007). mPTP is also involved in the
pathogenesis of Ischemia/reperfusion injury (IRI) (Morciano
et al., 2015). For example, a moderate injury, which occurs
in the case of a short ischemic period, may lead to a short
pore opening time thereby triggering apoptosis. On the other
hand, a more severe and persistent insult such as a longer
hypoxic event may lead to persistent pore opening inducing
cell death through necrosis. Myocardial infarction exhibits a
necrotic area at the core of the ischemic zone that is surrounded
by apoptotic markers, indicating decreased cardiomyocyte
survival upon an ischemic event (Javadov and Karmazyn, 2007;
Morciano et al., 2015). The mPTP structure remains an area of
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FIGURE 1 | Mitochondrial functions. Left panel: under physiological conditions, mitochondria functions are the core of bioenergetics activities, providing ATP
throughout the OXPHOS, which is also an important source of ROS. Basal ROS levels are maintained by the radical scavenging network. Additionally, mitochondria
are calcium-buffering organelles. Ca2+ homeostasis is finely controlled by its uptake through voltage-dependent anion-selective channel proteins (VDACs) and the
mitochondrial Ca2+ uniporter (MCU) complex, Ca2+ efflux is controlled by NCLX. Right top panel: pathological conditions, ROS burst and mitochondrial Ca2+
overload activate regulated cell death (RCD) inducing either apoptosis or necrosis pathway through the PTPC opening. Right-bottom panel: Ca2+ uptake
activates mitochondrial metabolism. Fatty acids are metabolized via FAO toward the TCA cycle providing energy as FADH2 and NADPH are building blocks for
biosynthesis. Voltage-dependent anion-selective channel proteins (VDAC), Mitochondrial Calcium Uniporter Complex (MCUC), Mitochondrial Na+/Ca2+ exchanger
(NCLX), oxidative phosphorylation (OXPHOS), Permeability transition pore complex (PTPC), ADP/ATP translocase (ANT) and peptidyl-prolyl cis-trans isomerase
Cyclophilin D (CypD), cytochrome C (cyt C), adenosine triphosphate (ATP), reactive oxygen species (ROS), tricarboxylic acid cycle (TCA), fatty acid oxidation (FAO), α
-ketoglutarate dehydrogenase (α-KG), oxaloacetate (OAA), Acetyl coenzyme A (Acetyl CoA) mitochondrial membrane potential (1ψm) (Created with BioRender.com).
intense study; the latest findings have been reviewed recently
by Bonora et al. (2020).
In the past few years, the mitochondrial F1/F0 ATP Synthase
(ATP synthase) has been recognized as a key component of pore
formation along with ADP/ATP translocase (ANT) and peptidyl-
prolyl cis-trans isomerase Cyclophilin D (CypD) (Figure 1;
Bonora et al., 2017; Morciano et al., 2017; Bonora and Pinton,
2019) that together regulate the opening of the permeability
transition pore complex (PTPC) (Bonora et al., 2020). It has
been demonstrated that dissociation of ATP synthase dimers
upon mitochondrial permeability transition (MPT) induction, in
particular the C subunit of the F0 part (in its c-ring form), is
a key component of the pore (Bonora et al., 2013, 2015, 2017).
Mitochondria isolated from Ppif -null mice strongly validates the
role of CypD as a pore regulator (Basso et al., 2005) because
these mitochondria are unresponsive to mitochondrial Ca2+
overload. Moreover, upon knocking out all three ANT isoforms
simultaneously MPT is inhibited (Karch et al., 2019). It remains
controversial whether ANT represents a key pore regulator or is
a part of the pore, and futher studies are needed to understand its
role in PTPC opening (Bonora and Pinton, 2019).
Thus, in order to avoid mitochondrial Ca2+ overload and
consequent activation of regulated cell death (RCD), Ca2+ uptake
has to be finely controlled. Ca2+ released by the ER rapidly
enters the mitochondrial intermembrane space (IMS) by Voltage-
dependent anion channels (VDACs), which are localized at the
OMM (Figure 1; Giorgi et al., 2018b). The channel exists in
three isoforms (VDAC1, VDAC2, VDAC3) expressed almost
ubiquitously among tissues with different sub-mitochondrial
ratios (Messina et al., 2012). It exhibits two conformations: the
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open pore conformation with a low transmembrane potential,
showing high-conductance and weak anionselective; whereas
increasing potential leads to a closed state conformation
characterized by cation selectivity and impermeable to nucleotide
passage (Giorgi et al., 2018b). In recent years, the mitochondrial
Ca2+ uniporter (MCU) was identified as a major player in
the regulation of mitochondrial Ca2+ homeostasis (Figure 1;
Kirichok et al., 2004). MCU is a multiprotein complex (MCUC)
situated at the IMM, which has a low affinity for Ca2+ ions
but is highly selective and regulated by auxiliar proteins that
make up part of the MCUC (Marchi and Pinton, 2014). MCUC
involvement in cardioprotection has been widely studied in
recent years: several mouse models with MCU deletions have
been developed including a cardiac-specific dominant-negative
MCU mouse that is expressed in neonates (Rasmussen et al.,
2015), a cardiac conditional MCU-KO mouse (Luongo et al.,
2015), and a tamoxifen-inducible cardiac-specific loss of MCU in
adult mice (Kwong et al., 2015). Mitochondria isolated from the
hearts of these mice are characterized by reduced mitochondrial
Ca2+ influx with subsequent reduced susceptibility to mPTP
opening and loss of mPTP-related cardioprotection (Kwong et al.,
2015; Luongo et al., 2015). On the contrary, deletion of NCLX,
a key component of Ca2+ release, is lethal to cells because
it induces mitochondrial Ca2+ overload and consequent PTP
opening (Luongo et al., 2015).
Mitochondria and Biosynthesis
Mitochondria contribute to cell metabolism by providing
building blocks for the synthesis of macromolecules necessary
for the maintenance of cellular homeostasis and cell growth.
As mentioned above, the TCA cycle represents a metabolic
engine in mitochondria where these catabolic and anabolic
reactions intersect (Martínez-Reyes and Chandel, 2020). As the
cycle runs, metabolic intermediates may be utilized for different
biosynthetic reactions (Figure 1; Spinelli and Haigis, 2018).
These biosynthetic reactions not only consume the TCA cycle
intermediates and direct them away from ATP production but
also require substantial energy input (Ritterhoff et al., 2020).
Thus, whether the intermediates will be used for synthetic
purposes is dependent on the energy state of the cell. Energy
requirements for sustained cardiac contractile function are high
and most of the cardiac metabolism is directed toward the
production of ATP (Doenst et al., 2013; Ritterhoff and Tian,
2017; Figure 1). Conversely, biosynthetic demands in non-
proliferative cardiomyocytes of the adult heart are rather low,
especially compared to highly proliferative cells such as cancer
cells (Karlstaedt et al., 2018). However, biosynthesis increases
considerably during cardiac hypertrophy (Karlstaedt et al., 2018;
Ritterhoff et al., 2020).
Whenever metabolic intermediates are removed from the
TCA cycle for biosynthetic reactions, they need to be restored
to ensure the cycle’s continued running (Martínez-Reyes and
Chandel, 2020). This replenishment of the intermediate pool
is named anaplerosis. Increased anaplerotic flux through
carboxylation of glycolysis-derived pyruvate to malate was
previously reported in hypertrophied rat hearts and paralleled
by elevated expression of malic enzyme, which catalyzes this
reaction (Sorokina et al., 2007; Pound et al., 2009). During
cardiac hypertrophy, there is an energy source switch from FAO
to increased glucose utilization, with a general reduction in
oxidative metabolism (Doenst et al., 2013; Ritterhoff and Tian,
2017; Ritterhoff et al., 2020). Taken together, increasing the use
of pyruvate for anaplerosis reduces its accessibility for oxidation
and may lead to energy inefficiency of the TCA cycle (Sorokina
et al., 2007; Pound et al., 2009), which contributes to contractile
dysfunction and subsequent heart failure. A better understanding
of how these mechanisms are regulated is needed for potential
targeted treatments of cardiac dysfunction.
ROS Generation and Regulation
Mitochondria are one of the important sources of ROS
production within most mammalian cells, including
cardiomyocytes (Figure 1; Chen and Zweier, 2014). Moreover,
interspecies comparisons performed in recent years show that
ROS regulatory systems are dependent on organism, type of
tissue, physiological state, age and pathological conditions to
finely tune the underlying responses (Barja, 1999). The primary
ROS generated in cardiac mitochondria is superoxide radical
anion (O2·−), which can be reduced through dismutation to
hydrogen peroxide (H2O2). Hydroxyl radicals (OH·) are also
generated from the decomposition of hydroperoxides, or by the
reaction of excited atomic oxygen with water. The mitochondrial
respiratory chain is a powerful endogenous source of O2·−, which
is a toxic by-product of oxidative phosphorylation (Figure 1).
Electrons from NADH and FADH2 flow through the electron
chain to reduce oxygen to form H2O (Figure 1). Large amounts
of O2·− are generated when oxygen is incompletely reduced due
to electron leaking at complexes I and III (Kussmaul and Hirst,
2006; Bleier and Dröse, 2013; Vinogradov and Grivennikova,
2016). Apart from the sites of ROS production within the
mitochondrial respiratory chain there are other mitochondrial
enzymes that generate either O2·− or H2O2. For example,
NADPH oxidase 4 (Nox4) is an important source of ROS in
heart mitochondria. Nox4 expression is upregulated in failing
cardiomyocytes and contributes to the increase of mitochondrial
O2·− levels that drives oxidative stress (Kuroda et al., 2010).
α-ketoglutarate dehydrogenase (α-KGDH) is one of the TCA
enzymes that is the most vulnerable to environmental changes
(Figure 1; Tretter, 2004). α-KGDH generates O2·− during
its catalytic function upon excessive NADH levels (Tretter and
Adam-Vizi, 2005), making α-KGDH an important mitochondrial
site for ROS production.
The ROS scavenging network coordinately works to
maintain proper basal ROS levels and redox signaling in
cells to control mitochondrial oxidative stress (Figure 1).
The mitochondrial antioxidant defense system includes
endogenous antioxidant enzymes such as superoxide dismutase,
catalase, glutathione peroxidase, glutathione reductase, and
the peroxiredoxin/thioredoxin system (discussed in greater
detail in Peoples et al., 2019). ROS are not only byproducts
of mitochondrial metabolism (Figure 1), but are commonly
involved as second messengers in cellular signaling impacting
both adaptive and maladaptive cardiomyocytes responses (Cave
et al., 2006). The redox-sensitive cellular processes are involved
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in cardiac development and differentiation, angiogenesis,
cardiac regeneration and cardiomyocyte apoptosis (Tretter,
2004). Indeed, basal levels of ROS are required for human
embryonic stem cells (ESCs) to differentiate into cardiomyocytes
(Ji et al., 2010). In particular, accumulating evidence points
to mitochondrial-mediated ROS generation as having a
key role in cardiomyocyte differentiation. Nox4-dependent
mitochondrial oxidative stress is one of the major pathways
activated in undifferentiated ESCs, driving their differentiation
into cardiomyocytes (Murray et al., 2013). Accordingly, Nox4
depletion in ESCs impairs cardiomyocyte differentiation (Li
et al., 2006). Another study demonstrated Nox4 expression
was significantly reduced in differentiated cardiomyocytes
(Crespo et al., 2010).
Oxidative stress signaling also orchestrates angiogenesis in
cardiomyocytes through Nox4 regulation. Nox4 is involved in
the stimulation of angiogenesis, protecting against contractile
dysfunction and hypertrophy under situations of chronic load-
induced stress (Zhang et al., 2010). Furthermore, functional
alterations of mitochondria and the subsequent increase of
ROS production are critical in cardiac repair and regeneration.
Postnatal heart maturation is associated with the transition
from glycolytic to oxidative metabolism, which drives an
increase in ROS production derived from the ETC and reduces
cardiomyocyte regeneration capacity (Puente et al., 2014). In
general, ROS levels are increased in response to heart damage
including ischemic injury (Chouchani et al., 2014; Puente et al.,
2014). Blocking ROS production and activation of scavenger
systems promotes heart regeneration after cardiac injury (Tao
et al., 2016). Conversely, mitochondrial dysfunction and the
subsequent increase of mitochondrial ROS cause cardiomyocytes
cell cycle arrest and activates apoptotic responses resulting in
lethal dilated cardiomyopathy (Yang et al., 2018; Zhang et al.,
2018). Overall, further insight into cellular mechanisms by which
mitochondrial redox signaling disturbs physiological oxidative
stress may uncover novel CVD therapeutic targets.
PHYSICAL AND FUNCTIONAL
COMMUNICATION
In adult cardiomyocytes mitochondria mobility is limited
with mitochondria moving along microtubule networks
(Frederick and Shaw, 2007). In most mammalian cells
mitochondria generally cluster around the nucleus (Yoon,
2004), but mitochondria can be at different cytoplasmic
locations leading to mitochondrial heterogeneity within
different cell types (Kuznetsov et al., 2009; Piquereau et al.,
2013). In cardiomyocytes, this heterogenous population can
be divided up into three separate populations, characterized
by their location within the cardiomyofibers: subsarcolemmal
mitochondria (SSM), intermyofibrillar mitochondria (IFM) or
perinuclear mitochondria (PNM) (Shimada et al., 1984). Electron
microscopy and transmission electron microscopy show these
distinct populations of mitochondria as the morphology is
unique for both their location and function (Shimada et al.,
1984; Manneschi and Federico, 1995; Vendelin et al., 2005;
Wikstrom et al., 2009). SSM are located just under the surface
sarcolemma and possess closely packed cristae. Holmuhamedov
and colleagues characterized and assessed SSM, finding that SSM
have a high sensitivity to Ca2+ overload-mediated inhibition of
ATP synthesis (Holmuhamedov et al., 2012). PNM are clustered
at nuclear pores between and around the two nuclei commonly
found in cardiomyocytes. Due to their well-developed curved
cristae, PNM have little matrix area that allows for higher ATP
production (Hackenbrock, 1966). Lu and coworkers provide
us with one of the few studies on PNM and found that PNM
morphology is more spherical than IFM and SSM, where the lack
of myofibrillar constraints allows for the PNM spherical shape
and its high mobility. This group also determined that PNM
are physically closer to protein synthesis sites for perinuclear
mitochondrial biogenesis, indicating that PNM are involved
in transcription and translation processes (Piquereau et al.,
2013; Lu et al., 2019). Lastly, IFM are very well organized, as
they lay closely parallel to contractile myofilaments. This highly
organized structure may cause IFMs to be restricted in their
position and mobility; however it also provides bioenergetic
support needed for contraction and mitochondrial interaction
with the cytoskeleton and the SR (Wilding et al., 2006). IFM
form an interface with the SR, which allows molecules to be
transported between the SR and mitochondria for effective signal
transduction (Eisner et al., 2013).
The SR is of extreme importance in cardiomyocytes, as it
critically regulates excitation-contraction coupling by releasing
its stored Ca2+ via the type 2 ryanodine receptor (RyR2) (Fu
et al., 2006; Figure 2). To understand the release of Ca2+ by the
SR, we will discuss the SR compartments. Structurally, the SR is a
diverse organelle, consisting of junctional, corbular, and network
SR. These components of the SR form a complex tubular network
where the network SR is formed by a series of interconnected
tubules that are located in the region between the transverse-
tubules (T-tubules) (Figure 2). The junctional SR is the domain
where specialized junctions are formed with the sarcolemma
T-tubules, allowing the SR to bring its ryanodine sensitive
Ca2+ channels (RyRs) in close range with the sarcolemma
voltage-gated L-type Ca2+ channels (Franzini-Armstrong and
Protasi, 1997; Franzini-Armstrong et al., 1999; Figure 2). The
corbular SR expresses RyRs as well, however it does not form
junctions with the sarcolemma (Vega et al., 2011). The membrane
depolarization, as a result of excitation-contraction (EC), causes
the L-type Ca2+ channels to open up close to the junctional
SR (jSR). This results in a small amount of Ca2+ entering the
limited cytosolic space that separates the SR and the T-tubule
sarcolemma. This increase in Ca2+ concentration exceeds the
threshold for the RyR2 to be activated through a mechanism of
Ca2+-induced Ca2+ release (CICR) (Figure 2; Fabiato, 1983).
This activation of a small number of clustered RyR2 affects
the concentration of intracellular calcium, inducing “calcium
sparks” (Cheng et al., 1993). When multiple “sparks” are activated
by the EC, a rise of intracellular calcium can be detected
in the dyadic cleft (Sharma et al., 2000), thereby initiating
myocardial contractions.
Interestingly, it has been reported that L-type Ca2+ channels
regulate mitochondrial functions through actin filaments
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FIGURE 2 | Sarcoplasmic reticulum-mitochondria communications. Sarcoplasmic reticulum (SR) is in close proximity to T-tubules and mitochondria. Depicted are the
channels involved in Ca2+ flux by which SR regulates excitation-contraction coupling and Ca2+ signaling with mitochondria. Microdomains where Ca2+ exchanges
occur are shown. Ryanodine Receptor 2 (RyR2) and L-Type Ca2+ Channels located at the t-tubule-SR interface; voltage-dependent anion-selective channel proteins
(VDAC) colocalize with RyR2 and also with L-Type Ca2+ channels, Mitochondrial Calcium Uniporter Complex (MCUC) is mainly located at the SR-Mito interface,
Rapid modes of Ca2+ uptake (RaM), ryanodyne receptor type 1 (mRyR1), Mitochondrial Na+/Ca2+ exchanger (NCLX) is located at the opposite side of MCUC near
the sarcoplasmic/endoplasmic reticulum Ca2+ ATPases (SERCA). Mitofusin1/2 (MFN1/2) function as SR-mitochondrial tethers (Created with BioRender.com).
(Viola and Hool, 2010). Viola and colleagues demonstrated
that Ca2+ influx through this channel increases superoxide
production, NADH levels, metabolism and also mitochondrial
membrane potential in a calcium independent pathway (Viola
et al., 2009). The cytoplasmic β-subunit of the L-type Ca2+
channel is anchored to the actin cytoskeleton. Disruption of this
tether decreases Ca2+ flux, leading to poor oxygen consumption
and ATP production by the mitochondria (Viola et al., 2009).
Moreover, this group found that cardiomyocytes isolated from
mdx mice (a mouse model of Duschennes muscular dystrophy
that in patients causes dilated cardiomyopathy) had impaired
communication between L-type Ca2+ and mitochondria through
an alteration in the cytoskeletal network that led to a decrease
in metabolic functions (Viola et al., 2014). They were the first to
show a physical and functional association between L-type Ca2+
and VDAC through F-actin (Viola et al., 2013, 2014; Figure 2).
They further reported that mdx cardiomyocytes maintain
a higher level of resting calcium and L-type Ca2+ channel
activation plays a role in the observed mitochondrial calcium
changes all of which may promote DCM (Viola et al., 2013).
Interactions between the SR and mitochondria play a key
role in cardiomyocyte contraction and multiple studies have
provided us with evidence of mitochondrial Ca2+ uptake,
and thus increased mitochondrial Ca2+ levels, in response
to SR-mediated Ca2+ release (Bassani et al., 1992; Negretti
et al., 1993; Szalai et al., 2000). As mentioned previously,
cardiac mitochondria uptake cytosolic Ca2+ through MCUC.
However, this channel requires at least a concentration of
2–5 µM of free Ca2+ in the SR’s bulk in order to be activated
(Kirichok et al., 2004). This Ca2+ concentration is reached only
within specific microdomains at the SR-mitochondria interface
(Figure 2). Specifically, in such extremely structured cells, MCUC
is expressed more in areas in close contact with the jSR, which
contain Ca2+-releasing RyR2 channels (Figure 2; De La Fuente
et al., 2016). Moreover, Ca2+ fluxes must be tightly regulated.
De la Fuente and colleagues demonstrated that MCUC and
NCLX are spatially excluded in cardiac mitochondria (Figure 2)
in order to optimize Ca2+ signals and sustain mitochondrial
metabolism required for cardiomyocyte contraction, while also
reducing the energy required for mitochondrial membrane
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potential depolarization (De La Fuente et al., 2016, 2018).
It remains controversial whether mitochondrial Ca2+ uptake
occurs quickly and synchronously with the cytosolic Ca2+
fluctuations in a beat to beat model (García-Pérez et al.,
2008) or if it increases slowly (Griffiths et al., 1997). The
differences between these two models rely on the experimental
approach used in terms of probes, stimulation and species
(De la Fuente and Sheu, 2019).
It should be noted that at the microdomain level, the
molecular bridge permitting Ca2+ exchange between SR-
Mitochondria is formed by RyR2 and VDAC2 channels (Figure 2;
Min et al., 2012). Moreover, in aged cardiomyoctes the physical
interaction between RyR2 and VDAC is significantly reduced,
leading to lower mitochondrial Ca2+ uptake, thereby promoting
oxidative stress and energy impairment (Fernandez-Sanz et al.,
2014). However, this event is independent of RyR2 and VDAC
expression levels and does not correlate with MFN2 levels
(Fernandez-Sanz et al., 2014).
It has become widely accepted that mitochondrial dysfunction
is associated with heart disease (Bonora et al., 2019). Pathological
SR-dependent Ca2+ leak through RyR2 channels is involved
in excessive mitochondrial Ca2+ uptake (Santulli et al., 2015;
Ruiz-Meana et al., 2019). Santulli et al. were the first to
show using a murine model that a feedback loop exists
between SR and mitochondria where Ca2+ leak through RyR2
channels causes mitochondrial Ca2+ overload and ROS burst
that enhances Ca2+ leak and thereby worsening mitochondrial
dysfunction (Santulli et al., 2015). Moreover, in human and
murine senescent cardiomyocytes, the SR-mitochondria Ca2+
exchange is significantly impaired due to RyR2 glycation (Ruiz-
Meana et al., 2019). These aged cardiomyocytes display a
deficient dicarbonyl detoxification pathway initiating Ca2+ leak
through RyR2 channels and further increasing mitochondrial
Ca2+ uptake. Taken together, this mechanism is involved
in the transition from a healthy cardiomyocyte to a failing
cardiomyocyte, as it may induce bioenergetic deficit through
mitochondrial damage leading to mitochondrial dysfunction
(Ruiz-Meana et al., 2019).
It is important to mention that MCUC is not the only manner
in which mitochondrial Ca2+ uptake occurs in cardiomyocytes.
Three different approaches of MCU-knockout mice (global
constitutive, cardiac-specific, dominant negative overexpression)
have been developed (Pan et al., 2013; Kwong et al., 2015;
Luongo et al., 2015). These models demonstrate that MCUC
is dispensable for heart function in basal cardiac activity,
while under “fight-or-flight” conditions MCU deletion shows
inhibition of acute mitchondrial Ca2+ uptake. Moreover, these
mice are highly protected from mPTP opening during ischemia-
reperfusion injury. Therefore, in basal resting conditions,
mitochondrial Ca2+ influx for maintaining ATP production
and cardiac metabolism occurs through other channels such as
rapid modes of Ca2+ uptake (RaM) (Buntinas et al., 2001) and
ryanodyne receptor type 1 (mRyR1) (Beutner et al., 2001, 2005;
Figure 2) both of which are located in the IMM. RaM displays a
faster Ca2+ uptake compared to MCUC (Buntinas et al., 2001),
while mRyR1 opens at lower cytosolic Ca2+ concentrations
(Beutner et al., 2001, 2005).
As discussed above, in cardiomyocytes SR-mitochondria Ca2+
transfer occurs mainly in areas of direct physical contact.
However, the proteins involved in the tethering have been poorly
investigated in the heart. Currently, mitofusin 2 (MFN2) is the
protein that has been suggested to tether this physical interaction
(Figure 2; Papanicolaou et al., 2011; Chen et al., 2012). It remains
a matter of discussion whether MFN2 acts as a tether or a
spacer at the ER/SR-mito interface. Two different MFN2-KO
mouse models have been generated showing opposite results.
When the gene deletion is made after birth the distance of SR-
mitochondria increased leading to a rise of Ca2+ concentration in
the SR (Chen et al., 2012). Moreover, isopronenterol stimulation
of cardiomyocytes, display an increase in cytosolic Ca2+
concentrations and lower mitochondrial Ca2 uptake. Of note, this
model does not show mitochondrial bioenergetic impairment
(Chen et al., 2012). On the other hand, if the gene is deleted
at the embryonic stage, there are no differences in the SR-
mitochondria distance and therefore, no alterations in Ca2+
fluxes. This result may be due to compensatory remodeling
(Papanicolaou et al., 2012). Each of these mouse models
demonstrates mitochondrial morphology alterations, contractile
depression and cardiac hypertrophy in the adults. However, more
studies are needed to investigate the role of MFN2 in tethering
SR-mitochondria and also to determine whether other proteins
may be involved in this tethering (Figure 2).
MITOCHONDRIA DYNAMICS
Fusion and Fission
Mitochondrial health is tightly correlated to the ability of these
dynamic organelles to move and change their morphology
in response to the surrounding environment (Ong et al.,
2017). The term “mitochondrial dynamics” refers to fusion and
fission processes of mitochondrial structures within a living
cell. Mitochondria constantly shape themselves through fusion
and fission in response to changes in energy requirements
(Hu et al., 2019). The balance between mitochondrial fusion
and fission determines the number (biogenesis), morphology
and activity of these multifunctional organelles (Marín-García
and Akhmedov, 2016). In the heart, rapid responses to body
demands depend on this balance of fusion and fission that
modulate multiple mitochondrial functions such as energy
production, ROS generation, Ca2+ homeostasis and cell death
(Marín-García and Akhmedov, 2016).
Several GTPases are involved in the fission and fusion
processes, which utilize GTP energy to guide conformational
changes (Urbani and Babu, 2019). Mitochondrial fission is
driven by dynamin-related protein-1 (Drp1) that is recruited to
mitochondria by human fission protein-1 (hFis1), mitochondrial
fission factor (Mff) and mitochondrial dynamics proteins 49
and 51 (MiD49 and 51) (Figure 3; Ong et al., 2017). This
process, characterized by the fragmentation of mitochondria
into more restricted and rounded organelles (Sharp and Archer,
2015; Sciarretta et al., 2018), is essential for mitosis and is
required for the specific clearance of injured mitochondria
through mitophagy (Ong et al., 2017). Specifically, in the heart,
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FIGURE 3 | Mitochondrial dynamics. Mitochondrial neworks are mantained by the balance betwen fusion (left panel) and fission (central panel). Damaged
mitochondria are cleared by mitophagy pathway (right panel). Dynamin-related protein-1 (Drp1), fission protein-1 (Fis1), mitochondrial fission factor (Mff),
mitochondrial dynamics proteins 49 and 51 (MiD49 and MiD51), mitofusin 1/2 (MFN1 and MFN2) optic atrophy 1(Opa1), PTEN-induced kinase 1 (PINK1) ubiquitin
ligase Parkin, phosphorylation (P), Ubiquitin (Ub), mitochondrial membrane potential (1ψm) (Created with BioRender.com).
mitophagy is used to preserve a healthy pool of mitochondria
under stress conditions (Nan et al., 2017). Mitochondrial outer
membrane fusion is directed by mitofusin 1 (MFN1) and
MFN2 and mitochondrial inner membrane fusion is executed by
optic atrophy 1(Opa1), leading to the formation of functional
elongated organelles (Figure 3; Ong et al., 2017). This process
is fundamental for mitochondrial DNA (mtDNA) maintenance
and inheritance, membrane potential transmission and Ca2+
signaling within the mitochondrial machinery (Westermann,
2010; Archer, 2013; Elgass et al., 2013; Hoppins, 2014). Of
note, in stress-free conditions neonatal and adult cardiomyocytes
demonstrate differences in the rate of mitochondrial dynamics.
Indeed, in neonatal cardiomyocytes fusion and fission processes
are more frequent and rapid compared to the levels observed
in adult cardiomyocytes (Forte et al., 2020). Mitochondria
in neonatal cardiomyocytes are highly mobile and distributed
throughout the cytoplasm within a filamentous network,
while adult cardiomyocyte mitochondria are more static and
spatially arranged into three subpopulations, as described above,
which constrains their movements (Vásquez-Trincado et al.,
2016). The homeostasis of mitochondrial dynamism is ensured
by the interaction and cooperation of the aforementioned
proteins. Moreover, alterations in the balance of mitochondrial
dynamics are correlated to cardiac disorders (Marín-García
and Akhmedov, 2016; Hu et al., 2019) leading to aberrant
mitochondrial network morphology.
Mitophagy
Mitophagy is a specific form of autophagy exploited by
the cellular machinery to digest dysfunctional and senescent
mitochondria through autophagosomes, under basal and stress
conditions (Shires and Gustafsson, 2015). This process is tightly
regulated by the mitochondrial PTEN-induced kinase 1 (PINK1)
and the cytosolic ubiquitin ligase Parkin. In Parkin-mediated
mitophagy, upon loss of 19m, PINK1 accumulates in the OMM
where it recruits Parkin (Figure 3). This may occur directly
by PINK1-mediated phosphorylation of Parkin (Koyano et al.,
2014) or indirectly by phosphorylation of MFN2 (Figure 3;
Chen and Dorn, 2013). Indeed, Matsua and colleagues reported
that upon a 19m decrease, cytosolic Parkin is recruited to
mitochondria by PINK1 through Parkin’s phosphorylation at
Ser65 within its ubiquitin-like domain. This phosphorylation
event is necessary for the efficient translocation of Parkin to
mitochondria (an initial step of mitophagy). Upon activation
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parkin initiates ubiquitination of mitochondrial proteins to
promote phagasome recruitment and subsequent degradation of
mitochondrial proteins by the lysosome (Figure 3; Kondapalli
et al., 2012; Shiba-Fukushima et al., 2012; Koyano et al., 2014).
It has also been observed that the phosphorylation of
MFN2 by PINK1 is essential for Parkin recruitment to
damaged mitochondria, thus suggesting a connection between
mitochondrial dynamics and mitophagy (Figure 3; Chen and
Dorn, 2013). A detailed discussion of mitophagy is reviewed
elsewhere (Shires and Gustafsson, 2015; Sciarretta et al., 2018).
Mitochondrial autophagy plays a critical cardioprotective role;
although when impaired it is detrimental to the heart (Saito
and Sadoshima, 2015; Morciano et al., 2020). In mouse hearts
lacking Mfn2 expression there is a reduction in Parkin-
mediated mitophagy and contractility and increased hypertrophy
leading to heart failure by 30 weeks of age (Song et al.,
2014). As mentioned previously, during ischemia/reperfusion
(I/R) mitophagy appears to protect the heart. Indeed, in a
cardiac-specific conditional Drp1 knockout mouse the inhibition
of the mitophagic flux causes accumulation of injured and
dysfunctional mitochondria, leading to cardiomyocyte death
during reperfusion (Ikeda et al., 2015). In addition, ablation of
Drp1 in adult mouse cardiomyocytes dampens mitochondrial
fission and significantly upregulates Parkin, which leads to
mitophagy and lethal cardiomyopathy (Song et al., 2015).
Notably, loss of Parkin in adult mouse hearts did not affect
function. However, in neonates a lethal cardiomyopathy due
to defective mitophagy clearance of fetal mitochondria was
observed in cardiomyocyte-specific Parkin ablation within three
weeks after birth (Gong et al., 2015). Moreover, PINK1 deficiency
in mice leads to cardiac mitochondrial dysfunction and excessive
oxidative stress (Billia et al., 2011). These findings highlight
that PINK1/Parkin and the mitophagy machinery are crucial for
cardiac homeostasis. Moreover, mitophagy impairment results in
defective cellular homeostasis, leading to cardiomyopathy and
ultimately heart failure (Nan et al., 2017; Bonora et al., 2019).
DILATED CARDIOMYOPATHY and
MITOCHONDRIAL DYSFUNCTION
Cardiomyopathies are a heterogeneous condition, which effect
myocardial structure and function culminating in heart failure.
Due to the complexity of this disease its classification continues
to evolve. However, the scenario is not simple, since any attempt
at classification is limited by the criterion choice of classification
itself (phenotype, etiology, clinical, morphological, functional).
Additionally, the heterogeneity and all the overlapping forms
of cardiomyopathy make this work more complex (Report of
the WHO/ISFC task force on the definition and classification of
cardiomyopathies; WHO/ISFC, 1980; Maron et al., 2006; Thiene
et al., 2007; Arbustini et al., 2014).
Among all cardiomyopathies, dilated cardiomyopathy (DCM)
continues to lack proper characterization and understanding
(Merlo et al., 2019). It is presented with a mixed etiology and
high incidence of genetic mutations. Patients with dilated
cardiomyopathy may present with ventricular arrhythmias in the
absence of signs of heart failure. An arrhythmogenic indication
may be found in arrhythmogenic right ventricular (RV)
cardiomyopathy (ARVC) and left-dominant arrhythmogenic
cardiomyopathy, hypertrophic cardiomyopathy and LV
noncompaction all of which are associated with increased
risk of sudden cardiac death. Furthermore, DCM may
also occur in patients with mitochondrial cardiomyopathy
and metabolic disorders (Thiene et al., 2007; Merlo et al.,
2019). Moreover, new genetic mutations continue to be
identified for DC, its related peripartum cardiomyopathy and
those of the arrhythmogenic cardiomyopathies, including
ARVC, left-dominant arrhythmogenic cardiomyopathy,
and channelopathies (Sen-Chowdhry et al., 2008, 2010;
Spezzacatene et al., 2015).
In this section we will focus on how changes in mitochondrial
health are associated with dilated cardiomyopathy onset and
progression (Figure 4). Dilated cardiomyopathy characteristics
resulting from gene mutations have been identified in patients
with peripartum cardiomyopathy, metabolic disorders,
mitochondrial dynamics, OXPHOS dysfunction, Fatty acid
and cardiolipin metabolism (Barth’s syndrome), all of which
we will touch on here (Figure 4). In each of these syndromes
echocardiographic data points to dilated cardiomyopathy
presenting with left ventricular systolic dysfunction (left
ventricular ejection fraction of <45% or fractional shortening
of <30%) and cardiac hypertrophy. A number of mitochondrial
diseases including OXPHOS disorders (Marin-Garcia et al.,
2000; Alston et al., 2012, 2015; Jain-Ghai et al., 2013) and Barth
syndrome (Hoch, 1992; Spencer et al., 2006; Gebert et al., 2009;
Wang H.-Y.J. et al., 2014) correlate with the incidence of DCM,
suggesting mitochondrial function as a key prognostic in the
pathogenesis of DCM.
Dilated Cardiomyopathy Types and
Mitochondrial Dynamics
Dilated cardiomyopathy (DCM) is a leading cause of heart
failure worldwide with a higher incidence in underdeveloped
countries, however its prevalence varies due to geographic and
socioeconomic conditions (Bozkurt et al., 2016). It is a form
of heart disease that presents with dilation of the left or both
ventricles and leads to systolic dysfunction and subsequent heart
failure (Figure 4; Dellefave and McNally, 2010; De Paris et al.,
2019). DCM is also considered idiopathic if no other vascular
conditions such as hypertension are detected (Mestroni et al.,
1999). Between 20–35% of idiopathic DCM cases may be linked
to a family history with an inherited gene defect (Hershberger
et al., 2010). Primarily mutations in genes that are involved in
sarcomere structure and contractility, cytoskeletal arrangement,
electrolytes balance and mitochondrial function (De Paris et al.,
2019) are linked to DCM. In DCM, the cardiac muscle becomes
thin and weakened causing the open area of the chamber to
become enlarged. As a result, the heart is unable to pump
blood efficiently (NIH, 2020). In order to maintain cardiac
output, ventricular volumes increase and sarcomere contractility
is reduced thereby, producing the thin-walled dilated appearance
that characterizes DCM (De Paris et al., 2019). This ventricular
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FIGURE 4 | Dilated cardiomyopathy. Schematic representation of the primary pathway of cardiomyocyte mitochondrial dysfunction, which induces dilated
cardiomyopathy (DCM). Metabolic imbalance, ROS overproduction and dysregulation of Ca2+ homeostasis are key changes inducing dilated cardiomyopathy. These
overall changes cause increased mitochondrial fission events and activation of cardiomyocyte apoptosis. Voltage-dependent anion-selective channel proteins
(VDAC), Mitochondrial Calcium Uniporter Complex (MCUC), Mitochondrial Na+/Ca2+ exchanger (NCLX), oxidative phosphorylation (OXPHOS), adenosine
triphosphate (ATP), reactive oxigen species (ROS), tricarboxylic acid cycle (TCA), fatty acid oxidation (FAO), Glucose transporter type 4 (GLUT-4), mitochondrial
membrane potential (1ψm), cytochrome C (cyt C) (Created with BioRender.com).
remodeling is driven by irregular cardiomyocyte pathophysiology
encompassing cardiomyocyte hypertrophy, impaired calcium
cycling, apoptosis and fibrosis. A decrease in cardiac efficiency,
as measured by myocardial oxygen consumption, leads to
a progressive weakening of energy-starved cardiac myocytes
pushing the heart toward heart failure (De Paris et al., 2019;
Chen, 2020).
Because the heart is an organ requiring a high energy demand,
regulation of mitochondrial metabolism plays an important role
in the pathogenesis of this and other CVDs (Rosca and Hoppel,
2010). During the first stages of DCM, increased mitochondrial
number (Figure 4) acts as a compensating mechanism for
maintaining energy supply (Zak et al., 1980). However, the
number of mitochondria declines during DCM progression
leading to a reduction in ATP, decreased contractility and
increased ROS all of which results in diastolic dysfunction
and heart failure (Flarsheim et al., 1996; Goffart et al., 2004;
Figure 4). Oxidative stress that presents as a consequence of
increased ROS production is a key part of the pathogenesis
of DCM. In vitro studies on isolated rat cardiomyocytes
determined that physiologic stretch induces a Ca2+ spike through
activation of NADPH Oxidase 2 (NOX2) and subsequently
the ryanodine receptors in the SR. The authors found
that in healthy cardiomyocytes, NOX regulation of ROS
production plays a beneficial role through oxidation of the
RyR2 channel, which mediates cardiac Ca2+-induced Ca2+
release (Figure 2). However, in muscular dystrophy mdx diseased
cardiomyocytes these Ca2+ sparks induce arrhythmogenic Ca2+
waves (Prosser et al., 2011). Moreover, in an mdx mouse
model of Duchenne muscular dystrophy Ca2+ release led to
hyperactive ROS and subsequent cardiomyopathy. Whether
this occurs in DCM remains to be determined. However, in
patients with DCM, NADPH-upregulation of NOX increases
ROS production through elevated rac1-GTPase activity (Maack
et al., 2003). Furthermore, isolated ventricular cardiomyocytes
from a rabbit heart failure model display decreased Ca2+
uptake resulting in reduced mitochondrial NADPH availability
(Despa et al., 2002). Decreased NADPH subsequently increases
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ROS (Kohlhaas et al., 2010; Figure 4). Taken together, these
findings point to Ca2+ controlled uptake at the mitochondria
as a key regulator of ROS and an imbalance in NADPH-
ROS causes disturbances in excitation-contraction coupling
leading to cardiac dysfunction (Sag et al., 2013) and heart
failure. ROS overproduction may also induce myocardial fibrosis,
which is a common factor in DCM patients presenting with
diastolic and systolic dysfunction (Assomull et al., 2006; Herpel
et al., 2006). Cardiac stress, in general, plays a key role in
initiating intrinsic apoptotic mechanisms in cardiomyocytes
through mitochondrial dysfunction (Green and Reed, 1998). As
detailed in previous sections dysfunctional mitochondria are
efficiently removed by mitophagy in cardiomyocytes for cell
maintenance and survival (Figure 3; Vásquez-Trincado et al.,
2016). However, during cardiac stress, autophagy flux is reduced
and damaged mitochondria accumulate resulting in enhanced
oxidative stress and cardiomyocyte apoptosis (Figure 4; Campos
et al., 2016). Uncontrolled autophagy is a component of the
pathogenesis of DCM, cardiac hypertrophy and ischemic heart
disease (Chistiakov et al., 2018).
Mitochondrial Fusion and Fission
Alterations in Dilated Cardiomyopathy
The role of mitochondrial morphological alterations in the
physiopathology of cardiomyopathies have become more
apparent in recent years with changes in mitochondrial fission
and fusion being at the forefront. Mitochondrial fission and
fusion proteins are essential for normal cardiac remodeling and
homeostasis (Chen et al., 2011). Impairments in mitochondrial
morphology and function due to genetic deletion of fission
and fusion proteins and their interacting partners may lead to
dilated cardiomyopathy and heart failure (Nan et al., 2017; Ong
et al., 2017; Hernandez-Resendiz et al., 2020). Dynamin-related
protein 1 (DRP1) is involved in controlling mitochondrial fission.
Genetic ablation of the Drp1 gene is embryonically lethal at day
E12.5 (Manczak et al., 2012), however cardiac-specific deletion of
Drp1 in the murine adult heart triggers mitochondrial elongation
and mitophagy suppression leading to a higher susceptibility to
ischemia/reperfusion and cardiomyopathy (Ikeda et al., 2015).
Further studies demonstrated that Python mutant mice with
a Drp1 gene point mutation (C425F) develop mitochondrial
defects and DCM, as a result of diminished mitochondrial fission
and mitophagy (Cahill et al., 2015). This C452F mutation is
within the M domain, which is highly conserved and involved
in protein-protein interactions (Cahill et al., 2015). Moreover,
mice deficient in the mitochondrial fission regulator Mff also
develop DCM leading to heart failure and death. Interestingly,
the simultaneous deletion of mitochondrial fission and fusion
regulator genes MFF (mitofission) and MFN (mitofusin) rescued
Mff knockout mice, with improved cardiac function, enhanced
mitochondrial oxidative capacity and increased survival
(Chen et al., 2015).
In regards to fusion, cardiac-specific ablation of mitofusins
Mfn1 and Mfn2 in mouse embryos causes death at days
E9.5–10.5 (Chen et al., 2011). At late embryonic stage,
the genetic inactivation of both these mitofusins promotes
mitochondrial dysfunction leading to the development of a
lethal cardiomyopathy; possibly due to biogenesis alterations,
diminished mtDNA and enhanced mitochondrial fragmentation
(Papanicolaou et al., 2012). Furthermore, conditional cardiac
Mfn1/Mfn2 gene deletions in adult mouse hearts present with
mitochondrial fragmentation, mitochondrial respiratory chain
deterioration and develop a lethal DCM. Interestingly, loss of
the Mfn1 gene alone is well tolerated in mice (Papanicolaou
et al., 2011; Chen et al., 2012), whereas Mfn2-null mice
display mitochondrial enlargement (Chen and Dorn, 2013),
increased ROS production (Song et al., 2014) and cardiac
hypertrophy (Papanicolaou et al., 2011). Proteolytic processing
of fusion protein Opa1 also plays a critical role in the
regulation of mitochondrial fusion. Opa1 proteolysis by stress-
activated OMA1 peptidase induces mitochondrial fragmentation
and DCM onset in a cardiac-specific Yme1l peptidase-null
mouse (Wai et al., 2015). Taken together, alterations in
mitochondrial fusion and fission machinery in the heart
promotes mitochondrial metabolic impairments that induce
dilated cardiomyopathy.
Dilated Cardiomyopathy: Subtypes and
Syndromes
Peripartum Cardiomyopathy
Peripartum cardiomyopathy (PPCM) is a rare form of DCM that
develops in the last month of pregnancy or within five months
postpartum. It presents with left ventricular systolic dysfunction
(left ventricular ejection fraction of < 45% or fractional
shortening of <30%) and cardiac hypertrophy (Satpathy et al.,
2008). PPCM occurs in the absence of any identifiable cause and
is exclusive to patients with no prior history of heart disease
(Crane, 1976; Hibbard, 1999). PPCM occurs worldwide with
an incidence of 1:1,000 births (Sliwa et al., 2017; Cunningham
et al., 2019) with its incidence varying geographically being
the highest in the United States, South Africa, Nigeria, and
Haiti. In the US, its incidence is 1:2,230 live births (Mielniczuk
et al., 2006; Brar et al., 2007; Gunderson et al., 2011; Kolte
et al., 2014; Cunningham et al., 2019). Mortality also varies
depending location with an estimate of 3–40% of patients
diagnosed with PPCM Although it is a condition of unknown
etiology, it also occurs in women with a previous history of pre-
eclampsia or as a result of multiple pregnancies (Kolte et al., 2014;
Arany and Elkayam, 2016).
PPCM shares many similarities with DCM including clinical
symptoms such as ventricular dilation and systolic dysfunction
(Figure 4; Pearson et al., 2000; Elliott et al., 2007). However,
both diseases differ in progression and outcome and there are
molecular differences. Similar to DCM, oxidative stress plays a
key role in the pathogenesis of PPCM in patients and in mouse
models in which ROS levels are highly increased compared to
controls. According to Hilfiker-Kleiner and colleagues (Hilfiker-
Kleiner et al., 2007), one possible reason for this increase is
due to a cardiomyocyte-specific deletion of signal transducer
and activator of transcription 3 (STAT3) as studied in a
mouse model of PPCM. In these mice downregulation of
the antioxidant Manganese superoxide dismutase (MnSOD)
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increases ROS production within mitochondria, which activates
Cathepsin D that cleaves prolactin (PRL, 23 kDa) into a
smaller 16 kDa piece. This negatively affects cardiomyocyte
microvasculature and metabolism in these mice (Hilfiker-Kleiner
et al., 2007, 2012; Hilfiker-Kleiner and Sliwa, 2014). STAT3 levels
are downregulated in PPCM patient hearts suggesting that its
expression may be cardioprotective during pregnancy (Ricke-
Hoch et al., 2013). Importantly, PLR levels increase and remain
high toward the end of pregnancy and after delivery which is
in accord with the development of PPCM (Grattan et al., 2008).
PPCM patients present with changes in PRL as well (Hilfiker-
Kleiner et al., 2007; Haghikia et al., 2013) suggesting an oxidative
stress plays a key role in PPCM.
A different mouse model of PPCM containing a cardiac
specific deletion of PPARγ coactivator-1α (PGC-1α) showed that
MnSOD was also reduced in the heart thus increasing ROS
production and resulting in disturbed mitochondrial metabolism
(Patten et al., 2012). Although research in cardiomyopathy-
related genes have begun to elucidate the pathogenesis of PPCM,
the molecular mechanisms underlying the development and
progression of PPCM and development of targeted therapies have
yet to be elucidated.
Early case studies in cardiomyopathy-related genes identified
a clinical overlap between PPCM and DCM, however the extent
of this interconnection remains unknown (Lee and Judge, 2017).
More recent studies have reported that mutations in cardiac
sarcomere proteins are a pathogenic cause of PPCM. These
mutations include deleterious truncations in the titin encoding
TTN gene that is a clinical feature shared with idiopathic DCM
(van Spaendonck-Zwarts et al., 2014; Ware et al., 2016; Ballard,
2019). Titin is part of the structural organization and assembly
of the sarcomere from the Z-disc to the M-line along with
other developmental, regulatory and mechanical functions in
cardiac and skeletal muscle (Lee and Judge, 2017). Mutations
in many sarcomeric proteins located at the Z-disc may also
lead to cardiomyopathies (Knöll et al., 2002; Frank et al., 2006;
Sheikh et al., 2007). For example, mutations in the myosin
heavy chain 7 (MYH7) gene that encodes the sarcomeric protein
β-Myosin Heavy Chain (β-MHC) cause PPCM (Walsh et al.,
2010; Fiorillo et al., 2016; Bollen and van der Velden, 2017).
β-MHC forms the heavy chain structure of type II myosin in
sarcomeres, which in a sliding mechanism with actin filaments,
generates the mechanical forces needed for muscle contraction.
Mutations in the STAT3 gene have also been found to contribute
to PPCM (Ballard, 2019; Harhous et al., 2019). Other genes in
which mutations have been reported to be associated with PPCM
onset and progression include truncations in DMD (dystrophin
that causes Duchenne’s Muscular Dystrophy) (Cheng and Prior,
2013; Ahmed et al., 2016), DSP (desmoplakin) (Ware et al.,
2016), TPM1 (α-tropomyosin)(Ware et al., 2016), and missense
mutations in MYBPC3 (cardiac myosin binding protein C)
(Morales et al., 2010), TNNC1 (cardiac troponin C) (Mestroni
et al., 1994), TNNT2 (cardiac troponin T) (Morales et al.,
2010), and LAMP2 (lysosome-associated membrane protein)
(Ware et al., 2016). This list of gene mutations causing PPCM
continues to grow as more genes are identified (Lee and
Judge, 2017; Ballard, 2019). Additional evidence supporting
an involvement of gene mutations in PPCM includes familial
incidence, genome-wide association studies and variability of
occurrence of PPCM among women from different regions and
ethnicities (Lee and Judge, 2017).
Metabolic Disorders and Dilated
Cardiomyopathy
Metabolic cardiomyopathy is a heart muscle disorder that
primarily develops in the presence of chronic metabolic
conditions, such as type 2 diabetes, obesity, and insulin resistance
(Figure 4; Nishida and Otsu, 2017). These conditions are
frequently overlapping, resulting in similar metabolic-related
structural and functional cardiac alterations, independent of
hypertension or coronary artery disease and are collectively
referred to as diabetic cardiomyopathy (Nakamura and
Sadoshima, 2020). During the early stage of this disorder,
metabolic disturbances do not cause significant structural
changes in the heart, but result in other cellular abnormalities
(e.g., impaired mitochondrial function, oxidative and ER stress
and altered Ca2+ handling) all of which contribute to changes in
diastolic function (Figure 4; Nishida and Otsu, 2017). However,
as the disease progresses, these abnormalities accumulate,
culminating in cardiomyocyte death, hypertrophy, fibrosis,
and diastolic and systolic dysfunction (Riehle and Bauersachs,
2019; Tan et al., 2020; Figure 4). The etiology of metabolic
cardiomyopathy is multifactorial and has been previously
reviewed (Nishida and Otsu, 2017; Riehle and Bauersachs, 2019;
Nakamura and Sadoshima, 2020; Tan et al., 2020).
In the presence of obesity, type 2 diabetes, or insulin
resistance, the heart functions with a dysregulated energy
metabolism. More specifically, impaired insulin-receptor
signaling leads to reduced translocation of glucose transporter
4 to the cell membrane resulting in reduced glucose uptake
and availability for oxidation (Figure 4; Cook et al., 2010; Tan
et al., 2020). On the other hand, increased fatty acid uptake
(Figure 4) and utilization occur due to increased membrane
localization of fatty acid translocase (FAT/CD36) and higher
PPAR-α activity (Coort et al., 2004; Nakamura et al., 2019;
Riehle and Bauersachs, 2019), which induces the expression
of genes involved in fatty acid uptake and oxidation and
further prevents glucose oxidation through stimulation of
pyruvate dehydrogenase kinase 4 expression (Nakamura and
Sadoshima, 2020). Consequently, high rates of FAO and loss
of glucose availability increase oxygen consumption, impair
cardiac efficiency, and induce mitochondrial ROS production
(Figure 4; Boudina et al., 2007; Borghetti et al., 2018). This
imbalance between fatty acid uptake and oxidation leads to
excessive accumulation of lipids and lipotoxic intermediates
(e.g., ceramides) in cardiomyocytes, which has been associated
with increased ROS levels, ER stress, mitochondrial membrane
remodeling, and cardiomyocyte apoptosis (Figure 4; Bikman and
Summers, 2011; Wende et al., 2012; Riehle and Bauersachs, 2019).
Under hyperglycemic conditions, toxic glucose intermediates
may contribute to the generation of advanced-glycosylation
end products (AGEs) that trigger enhanced proinflammatory
and profibrotic signaling in the heart (Singh et al., 2001;
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Nakamura and Sadoshima, 2020). These pathways promote
increased extracellular matrix (ECM) protein production and
reduced activity of ECM-degrading enzymes, both of which
contribute to cardiac fibrosis and contractile dysfunction
(Westermann et al., 2007; D’Souza et al., 2011; Borghetti
et al., 2018). Additionally, activation of the renin-angiotensin-
aldosterone system increases angiotensin II that stimulates
cardiac fibrosis and hypertrophy (Kumar et al., 2012).
Despite the significant body of research reporting various
possible mechanisms contributing to metabolic cardiomyopathy,
the pathology of this disorder is still not entirely understood.
Several studies have proposed that diabetes-induced changes
in mitochondrial function lead to cardiomyopathy. A detailed
review by Schilling (2015) discusses the hypothesis that diabetes
promotes mitochondrial dynamic dysregulation, which is a
trigger in the development of diabetic-induced cardiomyopathy
progression and heart failure. However, more mechanistic studies
are needed to confirm this hypothesis and understand the
underlying pathobiology to advance treatment with targeted
therapeutics. It should be noted that in a broader context,
metabolic cardiomyopathy can also develop as a consequence
of different inherited metabolic storage disorders that manifest
during childhood (Albakri, 2019). However, their pathology
differs from systemic disease-related cardiomyopathy and
involves altered energy production due to deficiencies in certain
enzymes regulating glycogen, glycolipid, and glycosaminoglycan
metabolism (Guertl et al., 2001; Albakri, 2019).
Mitochondrial-Associated Dilated
Cardiomyopathy
Approximately 50% of patients suffering with mitochondrial
diseases also present with cardiomyopathy (Florian et al.,
2015). In many cases mitochondrial cardiomyopathies have
an underlying genetic component resulting in malfunction of
mitochondrial respiratory chain, FAO or cardiolipin synthesis
and alterations of mitochondrial dynamics (El-Hattab and
Scaglia, 2016a; Figure 4).
Dilated Cardiomyopathy Associated With OXPHOS
Dysfunction
Taking into account that cardiac muscles are one of the
high energy tissues in the body, it is not surprising that
mitochondrial disorders associated with OXPHOS dysfunction
manifest as cardiomyopathy (Figure 4; Thorburn et al., 2004).
Moreover, mitochondrial disorder-related cardiomyopathies may
be associated with defects in the synthesis of coenzyme Q10
(Potgieter et al., 2013), synthesis of the OXPHOS Fe–S clusters,
transport of adenine nucleotides across IMM maintenance of
mtDNA, transfer of mitochondrial RNAs, ribosomal proteins,
ribosomal RNAs and translation factors (El-Hattab and Scaglia,
2016b). Mutations in the genes encoding mitochondrial proteins
often lead to aberrant OXPHOS machinery resulting in not only
an ATP deficiency but also increased ROS production and/or
alterations in the antioxidant defense system, nitric oxide (NO)
deficiency and dysregulation of Ca2+ homeostasis (El-Hattab and
Scaglia, 2016a,b).
Dilated Cardiomyopathies Associated With Fatty
Acid Oxidation Alterations
The energy substrates primarily used by the heart include fatty
acids and carbohydrates; however fatty acids are the main
energy substrate for the heart and they provide the majority of
cofactors crucial for mitochondrial oxidative phosphorylation.
All things considered, it is not surprising that alterations in the
mitochondrial FAO pathway lead to the development of heart
failure. Fatty acid and glucose metabolism are interconnected to
regulate each other in a process referred to as the glucose/fatty
acid cycle often called Randle Cycle (Randle et al., 1963; Arslanian
and Kalhan, 1994). Interestingly, in the heart an increased rate
of FAO decreases glucose oxidation and conversly an increased
rate of glucose oxidation inhibits FAO (Figure 4). Alterations
in key enzymes involved in FAO lead to mitochondrial
cardiomyopathy. These enzymes include very long-chain acyl-
CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA
dehydrogenase (LCHAD); trifunctional protein (TFP); carnitine-
acylcarnitine translocase (CACT); carnitine palmitoyltransferase
type 2 (CPT2); carnitine transporter (CT) and multiple acyl-
CoA dehydrogenase (MAD) (Merritt et al., 2018). In the case
of diabetic cardiomyopathy (where an oversupply of fatty acids
is responsible for the observed cardiac lipotoxicity) excess
fatty acids promote accumulation of lipid intermediates and
surprisingly, in the case of diabetes, it is accompanied by
increased FAO (Figure 4; Fillmore et al., 2014).
Dilated Cardiomyopathy Associated With Cardiolipin
Synthesis Dysregulation
Cardiolipin is an essential constituent of IMM and contributes
up to 20% of total IMM lipids (Schlame and Greenberg,
2017; Tatsuta and Langer, 2017). Due to the fact that IMM
is comprised of approximately 75% protein and 25% lipid,
alterations in the cardiolipin content and/or its composition have
a direct impact on the structure and properties of the IMM
and influence many mitochondrial processes including oxidative
phosphorylation and protein translocation to mitochondria.
Cardiolipin is essential (other phospholipids cannot substitute
for it) for optimal function of the mitochondrial respiratory
chain complexes I, III, and IV and is required for the structural
integrity and formation of respiratory chain supercomplexes
(Figure 4; Pfeiffer et al., 2003; Dudek et al., 2013; Letts et al.,
2016). Moreover, changes in cardiolipin content or its’ species
composition contribute to higher ROS production (Paradies
et al., 2004; Nickel et al., 2014). Interestingly, mutations in the
DNAJC19 gene encoding a component of the mitochondrial
protein import machinery in the IMM also induces cardiolipin
accumulation with altered acyl chain. This is most likely due
to DNAJC19’s interaction with prohibitins (PBH) to regulate
cardiolipin remodeling (Richter-Dennerlein et al., 2014).
Barth Syndrome (BTHS) is a rare X-linked recessive
mitochondrial cardiomyopathy caused by an altered cardiolipin
metabolism. BTHS pathology includes changes in mitochondrial
membrane phospholipids, lactic acidosis, organic aciduria and
skeletal muscle weakness. BTHS is linked to gene mutations
in the phospholipid transacylase localized to mitochondria,
taffazzin (TAZ) (Dudek and Maack, 2017) and is involved in
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cardiolipin acyl chain remodeling. In physiological conditions
up to 90% of cardiolipin in cardiac mitochondria exist as
tetralinoleoylcardiolipin. Decreases in tafazzin activity reduce
cardiolipin abundance and increase monolysocardiolipin levels.
There are several detailed reviews on BTHS and cardiolipin





Overall patients presenting with dilated cardiomyopathy
continue to progress to end stage heart failure (1:3 patients)
with disease maintenance occurring in 1:4 patients. Currently, a
heart transplant is the best treatment option because there are
no targeted therapies available due to the high complexity of
dilated cardiomyopathy (Begic et al., 2018). Targeted therapies
need to be developed that treat this complex disease potentially
by targeting the underlying molecular pathways that are
dysregulated. For example, targeting the OXPHOS pathway
and subsequent mitochondrial dysfunction may be a way to
attenuate cardiomyocyte death and maintain cardiac function
(Brown et al., 2017). Advances in genetic analysis and molecular
pathway alterations due to these gene mutations has paved the
way for early detection and focused research on the development
of potential preventative therapies (Verdonschot et al., 2019).
Currently, mitochondrial-specific targeting therapies for dilated
cardiomyopathy have not yet entered the clinic as they are
at the basic research level. As research continues it will help
determine whether restoring mitochondrial function may be way
an efficacious way to treat dilated cardiomyopathies.
One research area that has emerged recently is the
development of cardiac-specific organoids to study the
complexities of cardiovascular disease. The term organoid is
used to describe in vitro 3D multicellular tissues generated from
pluripotent and adult stem cells that recapitulate some of the key
structural and functional features of their in vivo counterparts
(de Souza, 2018). Advances in efficient differentiation of induced-
pluripotent cells (iPSC) into several cardiac cell types provide
a novel unlimited cell source for developing cardiac organoids,
especially due to the difficulties of adult stem cell isolation
and ethical concerns regarding embryonic cells (Moretti et al.,
2013; Zamani et al., 2018). Unlike traditional 2D cell cultures,
cardiac organoids provide more accurate representations of the
complexity of cell-cell and cell-extracellular matrix interactions.
Moreover, being derived from human stem cells, they reflect
cardiac (patho)physiology more appropriately compared
with animal models thereby helping to overcome substantial
functional between-species differences and animal to human
translation issues (Moretti et al., 2013).
To date, iPSC cells and derived 3D organoids are used to
model several cardiac disorders caused by cardiomyocyte gene
mutations including dilated cardiomyopathy, hypertrophic
cardiomyopathy, Barth’s syndrome and glycogen-storage
cardiomyopathy (Wang G. et al., 2014; Hinson et al., 2015,
2016; Cashman et al., 2016; Nugraha et al., 2019). In addition to
these monogenic diseases, cardiac organoids may provide great
promise for modeling complex, lifestyle-related heart pathologies
including acute myocardial infarction (Richards et al., 2020)
and cardiomyopathy. For instance, relevant in vitro models of
metabolic cardiomyopathy should embody all of the key features
of the diabetic heart, including metabolic shift, lipotoxicity,
insulin resistance and altered functionality (contractility and
changes in mitochondrial function). Most of these characteristics
have been previously recapitulated in 2D in vitro models that
use iPSC-derived cardiomyocytes exposed to a diabetic-like
environment (Drawnel et al., 2014). However, iPSC-derived
cardiomyocytes are somewhat immature, with a fetal-like profile,
which relies primarily on glucose utilization, compared to adult
cardiomyocytes where metabolism depends on FAO. Ideally, a
model of metabolic cardiomyopathy would provide evidence
of this metabolic switch, which may be challenging to achieve
using iPSC-derived cardiomyocytes (Jiang et al., 2018; Granéli
et al., 2019). Nevertheless, considerable advances have been
made in overcoming this issue of immaturity, especially using
3D culture, mechanical, or electrical conditioning techniques
that provide a more adult-like cardiomyocyte phenotype in
terms of oxidative metabolism, gene expression and calcium
handling (Ronaldson-Bouchard et al., 2018; Golforoush and
Schneider, 2020). Moreover, combining different cardiac cell
types into 3D tissue-like organoids promotes the maturity
and function of iPSCs-derived cardiomyocytes (Giacomelli
et al., 2017; Golforoush and Schneider, 2020). Recently, cardiac
organoids containing four different cell types (cardiomyocytes,
epicardial, endothelial cells, and cardiac fibroblast) derived
from the same iPSC have been created (Helms et al., 2019).
Furthermore, Lee and colleagues developed a 3D heart
organoid comprised of cardiomyocytes, conducting tissues,
endothelial and smooth muscle cells, with atrial and ventricular
parts, myocardial contraction, and gene expression profiles
resembling their in vivo counterparts (Lee et al., 2020). Further
research is necessary to determine how these organoids
may be used to accurately model the complex pathology
of dilated cardiomyopathy for a better understanding of
underlying molecular mechanisms, mitochondrial function and
identification of potential therapeutic targets.
CONCLUSION
Mitochondria are the central hub of the cell, controlling and
regulating several different functions such as bioenergetics,
biosynthesis, ROS production and cell death. Considering the
high-energy demand of the heart, much research has focused
on how mitochondria play a central role in maintaining
myocardial homeostasis. Morphological and functional changes
of mitochondria are associated with CVD. Therefore, a finely
tuned healthy mitochondrial network is required in order to
prevent CVDs. Mechanisms of surveillance are also required
to conserve mitochondrial fitness and alterations of this quality
control system, which requires a delicate balance between fusion-
fission machinery and mitophagy and loss of this balance,
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may lead to the accumulation of damaged and dysfunctional
mitochondria. Loss of healthy mitochondria in the heart is linked
directly with a decline of energy supply, increased ROS and
culminates with cardiomyopathy onset and heart failure.
To date, current therapies focus on reducing heart energy
demand and preventing further worsening of cardiac muscle
function (Acquatella, 2000; Verdonschot et al., 2019). Continued
research into the molecular mechanisms of CVD is needed to
develop targeted therapies. Indeed, the continuing development
of novel approaches such as organoids to study the aberrant
pathology of the heart will further our understanding of how
mitochondria are cardioprotective and identify new therapeutic
targets for treating and preventing cardiomyopathies.
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Krga, Glibetić, Pinton, Giorgi and Matter. This is an open-access article distributed
under the terms of the Creative Commons Attribution License (CC BY). The use,
distribution or reproduction in other forums is permitted, provided the original
author(s) and the copyright owner(s) are credited and that the original publication
in this journal is cited, in accordance with accepted academic practice. No use,
distribution or reproduction is permitted which does not comply with these terms.
Frontiers in Cell and Developmental Biology | www.frontiersin.org 21 January 2021 | Volume 8 | Article 624216
